Who was studied, and how
Three numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 1 other study
731people with type 2 diabetes, in this paper
The trial randomly assignedassigned by chance
tirzepatide
placebo
Probably reduced cardiovascular death or worsening heart failure events−38%
randomisedAmong patients with diabetes, the trial randomly assignedassigned by chance
tirzepatide
placebo
No clear effect on cardiovascular death or worsening heart failure events−36%
randomisedthe abstract, start to end
… frequently in the tirzepatide group (HR: 0.62; 95% CI: 0.41-0.95; P = 0.026), …
… or without diabetes was similar: HR of 0.64 (95% CI: 0.35-1.15) in patients with diabetes and 0.61 (95% CI: 0.33-1.10) in patients …
← favours treatmentfavours comparator →
could be chanceCardiovascular death or worsening heart failure eventstirzepatide vs placebo
HR 0.620.41–0.95
Cardiovascular death or worsening heart failure eventstirzepatide vs placebo, in patients with diabetes
HR 0.640.35–1.15
Cardiovascular death or worsening heart failure eventstirzepatide vs placebo, in patients without diabetes
HR 0.610.33–1.10
GIP/GLP-1 & amylin agonistsCardiovascular events
GIP/GLP-1 & amylin agonists × cardiovascular eventshelps?one trial
unlikelylikely
0.50only evidence
← favours comparatorfavours treatment →
1 / 6